广济药业拟定增募资6亿元

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) is facing significant operational challenges, including three consecutive years of substantial losses, a rising debt-to-asset ratio, and prolonged low prices for its core products, leading to a proposed A-share issuance to raise up to 600 million yuan for debt repayment and working capital replenishment [1][2]. Group 1: Financing and Share Issuance - The company plans to issue up to 94.937 million shares at a price of 6.32 yuan per share, with the total fundraising not exceeding 600 million yuan, aimed at optimizing capital structure and enhancing risk resistance [2]. - The sole subscriber for this issuance is the controlling shareholder, Changjiang Industrial Investment Group, which will increase its stake from 25.26% to 41.33%, further consolidating control over the company [2]. - The shares issued will have a lock-up period of 36 months, indicating the major shareholder's commitment to the company's long-term development [2]. Group 2: Financial Performance and Challenges - Guangji Pharmaceutical reported a net loss of 140 million yuan in 2023, which is expected to expand to a loss of 295 million yuan in 2024, with projections for 2025 indicating losses between 399 million and 518 million yuan [3]. - The company attributes its losses to intensified market competition, leading to persistently low sales prices for its main product, Vitamin B2, and insufficient sales volume to offset price declines [3]. - As of September 30, 2025, the company's debt-to-asset ratio reached 62.67%, significantly higher than the industry average, reflecting a precarious financial position [4]. Group 3: Debt Management and Financial Integrity - The high debt ratio has increased financing costs, prompting the company to seek multiple credit facilities from banks, including a 150 million yuan credit line from Minsheng Bank and a 230 million yuan credit line from Zheshang Bank [5]. - The company has faced scrutiny for financial misconduct, including improper revenue recognition practices that led to administrative penalties totaling 3.1 million yuan [6]. - Investors are concerned about the company's internal control deficiencies and the effectiveness of measures taken to restore market trust, as the company has not provided detailed updates on corrective actions [6][7].